BRADLEY PHARMACEUTICALS INC
10QSB, 2000-11-14
PHARMACEUTICAL PREPARATIONS
Previous: SUNAMERICA ASSET MANAGEMENT CORP, 13F-NT, 2000-11-14
Next: BRADLEY PHARMACEUTICALS INC, 10QSB, EX-1, 2000-11-14



                       U.S. Securities and Exchange Commission
                             Washington, D.C.  20549

                                   Form 10-QSB

(Mark One)

[X]   QUARTERLY REPORT PURSUANT SECTION 13 OR 15(d) OF THE SECURITIES
      EXCHANGE ACT OF 1934

For the quarterly period ended        September 30, 2000
                                      ------------------

[ ]   TRANSITION REPORT PURSUANT SECTION 13 OR 15(d) OF THE SECURITIES
      EXCHANGE ACT OF 1934

For the transition period from               to
      Commission file number                      0-18881
                                                  -------

                         BRADLEY PHARMACEUTICALS, INC.
                         -----------------------------
      (Exact name of small business issuer as specified in its charter)

                 Delaware                          22-2581418
                 --------                          ----------
      (State or other jurisdiction of          (IRS Employer
       incorporation or organization)           Identification No.)

                       383 Route 46 West, Fairfield, NJ
                       --------------------------------
                   (Address of principal executive offices)

                              	(973) 882-1505
                               --------------

                                    N/A
                                    ---
              (Former name, former address and former
               fiscal year, if changed since last report)

Check whether the issuer (1) filed all reports required to be filed by
section 13 or 15(d) of the Exchange Act during the past 12 months (or for
such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.
Yes _X_  No ___

State the number of shares outstanding of each of the issuer's classes of
common equity, as of the latest practicable date:

        Title of Each Class                   Number of Shares Outstanding
          of Common Stock                        as of November 1, 2000
        -------------------                   ----------------------------
        Common Stock, $.01 Par Value                   8,206,289
        Class B, $.01 Par Value                          431,552

Transitional Small Business Disclosure Format (check one):
Yes ___ 	No _X_

                            BRADLEY PHARMACEUTICALS, INC.

                               INDEX TO FORM 10 - QSB

                                 September 30, 2000


                                                                    Page
                                                                   Number
                                                                   ------
Part I - Financial Information

         Financial Statements (unaudited):

         Condensed Consolidated Balance Sheet -
         September 30, 2000                                           3

         Condensed Consolidated Statements of
         Operations - three and nine months ended
         September 30, 2000 and 1999                                  4

         Condensed Consolidated Statements of Cash
         Flows - nine months ended September 30, 2000
         and 1999                                                     5

         Condensed Notes to Consolidated Financial Statements         7

         Management's Discussion and Analysis                        11

Part II - Other Information

         Item 1.  Legal Proceedings                                  15
         Item 5.  Other Information                                  15
         Item 6.  Exhibits and Reports on Form 8-K                   15

         Signatures                                                  16

















                                           2



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission